Acadia Pharmaceuticals
Mark Schneyer is our Senior Vice President of Business Development and Chief Business Officer and has been with Acadia since May 2020. Mr. Schneyer joined us from Pfizer Inc. where he most recently was Vice President, Business Development, for the Upjohn division. Mr. Schneyer joined Pfizer’s Worldwide Business Development organization in 2011 and served in various business development positions of increasing responsibility. While at Pfizer, Mark led multiple strategic transactions, including licensing agreements, product acquisitions and divestitures, strategic collaborations and company acquisitions. Prior to Pfizer, he was an investment banker at Lazard and advised boards of directors and senior management teams in the healthcare sector. Mr. Schneyer earned a Bachelor of Science in Economics with a Concentration in Finance from the Wharton School of the University of Pennsylvania.
This person is not in any offices
Acadia Pharmaceuticals
3 followers
Acadia is trailblazing breakthroughs in neuroscience to elevate life. They are at the forefront of healthcare, fighting for breakthroughs in our science, their therapies and the way we work, but also in the lives of the people they serve. Acadia is committed to their purpose: we fight disease so more you shines through.